This study was carried out to evaluate the role of iron in the pathogenesis
of Parkinson's disease (PD) and to deterimine the role of bromocriptine
on iron concentration in PD patient serum as well as midbrain of experimental
animals. Results of the present work revealed that there was
non significant changes in serum iron level P>0.05, either in PD patient or
in PD patients under bromocriptine treatment. In experimental animals,
desferrioxamine (10 mg/ kg/LP. / day for 15 days) signcantly reduce
midbrain iron level (P<0.05) while bromocriptirte (1.4 mg/kg/ oral day for
15 days) non significantly affect iron level (P>0.05). In addition, induction
of PD in rats by single dose of fLuphenazine (10 mg/kg/S. C.) significantly
elevate the midbrain iron concentration, P<0.05. and in PD rats treated
with desferrioxamine there was significant reduction of midbrain iron level.
P<0.05, but in PD rats treated with bromocriptine, there was non significant
change in midbrain iron level, P>0.05. Moreover, concomitant administration
of desferrioxamine (10 mg/kg/LP), bromocriptine (1.4 mg/Ica
oral) with a single dose of fluphenazine (10 mg/kg/S.C.). there was significant
reduction P<0.05 of iron in the tested brain area, so, it can be concluded
that increased midbrain iron may participate in the development of
PD. Moreover, bromocrip tine not affect iron concentration in midbrain, and
desferrioxamine may be of a great value in the prophylaxis as well as the
management of P.D. |
